Despite Temporary Headwinds, Pharma Giant's Strong Dividend and Pipeline Promise Upside
• Market overreacted to revenue/EPS decline in 2023; decline solely due to cooling off of temporary COVID tailwinds
• Stock offers robust 6.3% dividend yield and massive upside potential per valuation analysis
• Company continues investing heavily in pipeline of new drugs, including promising oncology medicines
• Upcoming earnings still face declines, but Q2 may show positive dynamics as COVID impact fades
• Risks include weak sentiment and upcoming patent expirations, but company has long history of innovation